Abstract
Psoriasis and psoriatic arthritis are debilitating inflammatory immunemediated diseases which are chronic in nature and often require lifelong attention. Traditional therapies used to combat these diseases lack sufficient long-term efficacy and are associated with a number of toxicities. Failing to adequately satisfy both patients and physicians, traditional therapies have proven insufficient and have left few options. Etanercept is a tumor necrosis factor (TNF) antagonist that reduces elevated TNF levels by competitively binding to both TNF-α and TNF-β and inhibiting the proinflammatory cascade. Providing a valuable treatment option alone, etanercept can also be effectively administered in conjunction with traditional treatments. Etanercept is self administered by subcutaneous (SC) injection, making treatment less of a burden for patients by eliminating the need for frequent office visits and laboratory testing. Etanercept is approved in the US for the treatment of psoriasis, psoriatic arthritis, rheumatoid arthritis, juvenile rheumatoid arthritis, and ankylosing spondylitis.
Keywords: Anti-TNF, Enbrel®, Etanercept, Psoriatic arthritis, Psoriasis
Reviews on Recent Clinical Trials
Title: Use of Etanercept in the Treatment of Psoriasis and Psoriatic Arthritis
Volume: 1 Issue: 3
Author(s): Brian S. Fuchs and Suhail Hadi
Affiliation:
Keywords: Anti-TNF, Enbrel®, Etanercept, Psoriatic arthritis, Psoriasis
Abstract: Psoriasis and psoriatic arthritis are debilitating inflammatory immunemediated diseases which are chronic in nature and often require lifelong attention. Traditional therapies used to combat these diseases lack sufficient long-term efficacy and are associated with a number of toxicities. Failing to adequately satisfy both patients and physicians, traditional therapies have proven insufficient and have left few options. Etanercept is a tumor necrosis factor (TNF) antagonist that reduces elevated TNF levels by competitively binding to both TNF-α and TNF-β and inhibiting the proinflammatory cascade. Providing a valuable treatment option alone, etanercept can also be effectively administered in conjunction with traditional treatments. Etanercept is self administered by subcutaneous (SC) injection, making treatment less of a burden for patients by eliminating the need for frequent office visits and laboratory testing. Etanercept is approved in the US for the treatment of psoriasis, psoriatic arthritis, rheumatoid arthritis, juvenile rheumatoid arthritis, and ankylosing spondylitis.
Export Options
About this article
Cite this article as:
Fuchs S. Brian and Hadi Suhail, Use of Etanercept in the Treatment of Psoriasis and Psoriatic Arthritis, Reviews on Recent Clinical Trials 2006; 1 (3) . https://dx.doi.org/10.2174/157488706778250131
DOI https://dx.doi.org/10.2174/157488706778250131 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Meet the Guest Editor
Combinatorial Chemistry & High Throughput Screening Total Phenolic Content and In vitro Antioxidant Activity of Endophytic Fungi Isolated from Calotropis procera L.
Current Bioactive Compounds Platelet Biomarkers in Tumor Growth
Current Proteomics Enantiomeric Resolution of Ibuprofen and Flurbiprofen in Human Plasma by SPE-Chiral HPLC Methods
Combinatorial Chemistry & High Throughput Screening Novel and Emerging Drugs for Systemic Lupus Erythematosus: Mechanism of Action and Therapeutic Activity
Current Medicinal Chemistry Parvovirus B19 (B19V) Infection and Pregnancy
Current Pediatric Reviews Editorial (Thematic Issue: Optimizing Treatment in Rheumatoid Arthritis)
Current Pharmaceutical Design Potential Applications of FDG-PET/CT in COPD: A Review of the Literature
Current Molecular Imaging (Discontinued) Hsp90 Inhibition with Resorcylic Acid Lactones (RALs)
Current Topics in Medicinal Chemistry Voltammetric Determination of Sinomenine in Biological Fluid Using a Glassy Carbon Electrode Modified by a Composite Film of Polycysteic Acid and Carbon Nanotubes
Combinatorial Chemistry & High Throughput Screening Recent Patents on Metalloproteinases as Biomarkers in Osteoarthritis Diagnosis and Treatment
Recent Patents on Biomarkers VIP in Inflammatory Bowel Disease: State of the Art
Endocrine, Metabolic & Immune Disorders - Drug Targets Atorvastatin Sensitises Vascular Smooth Muscle Cells, but not Endothelial Cells, to TNF-α-induced Cell Death
Current Pharmaceutical Design Introduction from Editor-in-Chief
Current Rheumatology Reviews Interstitial Lung Disease in Systemic Sclerosis: A Single-center Retrospective Analysis
Current Rheumatology Reviews Cytotoxicity and Anti-Inflammatory Effects of Polyherbal Formulations, Joint Pain Spl and Rumalaya Forte on Lipopolysaccharide Induced Inflammation in IC-21 Macrophages
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Glyco-Engineering of Human IgG-Fc to Modulate Biologic Activities
Current Pharmaceutical Biotechnology Cytokine Gene Polymorphism in Heart Transplantation: A Review
Current Genomics “How to Manage Loss of Response to Anti-TNF in Crohns Disease?”
Current Drug Targets Meet Our Editorial Board Member
Current Rheumatology Reviews